Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™ [Yahoo! Finance]
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: Yahoo! Finance
in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress™ taking place in Milan, Italy from June 5-8, 2024. Title: Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial Late Breaker Abstract Number: LB27 Presenter: Michael Trauner, M.D., Chair of Gastroenterology and Hepatology, Department of Medicine III, Medical University Clinic, Vienna, Austria Presentation Date and Time: Wednesday, June 5, 2024, 8:30 a.m. – Saturday, June 8, 2024, 5:00 p.m. CEST Title: Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast targets TGF-beta inhibition to specific cell types in human liver explant tissue with biliary fibrosis Abstrac
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.MarketBeat
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisGlobeNewswire
- Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Citigroup Inc. from $45.00 to $44.00. They now have a "buy" rating on the stock.MarketBeat
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 5/14/24 - Form 8-K
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- PLRX's page on the SEC website